Cargando…
Adverse events after pleurodesis in patients with malignant pleural effusion
BACKGROUND: Malignant pleural effusion (MPE) is an important sign of advanced disease in metastatic cancer. Pleurodesis is one option to treat recurrent MPE. The Inflammatory response after pleurodesis may lead to important adverse events (AE) in a set of very ill patients. METHODS: Retrospective an...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399432/ https://www.ncbi.nlm.nih.gov/pubmed/32802429 http://dx.doi.org/10.21037/jtd-19-3850 |
_version_ | 1783566147756490752 |
---|---|
author | Terra, Ricardo Mingarini da Costa, Priscila Berenice Dela Vega, Alberto Jorge Monteiro Pêgo-Fernandes, Paulo Manuel |
author_facet | Terra, Ricardo Mingarini da Costa, Priscila Berenice Dela Vega, Alberto Jorge Monteiro Pêgo-Fernandes, Paulo Manuel |
author_sort | Terra, Ricardo Mingarini |
collection | PubMed |
description | BACKGROUND: Malignant pleural effusion (MPE) is an important sign of advanced disease in metastatic cancer. Pleurodesis is one option to treat recurrent MPE. The Inflammatory response after pleurodesis may lead to important adverse events (AE) in a set of very ill patients. METHODS: Retrospective analysis of patients submitted to pleurodesis (2009–2013). Clinical and laboratory data were collected. We compare the values in the day of pleurodesis, 2(nd), 5(th) and 10(th) days after. RESULTS: One hundred fourteen patients were undergone to pleurodesis with silver nitrate (46%), iodine (52%) and talc (2%). Female was the most frequent (86%) and the breast cancer was the most common primary site. The most frequent adverse event was low hemoglobin account (37), followed by pain (31). 68% of patients presented AEs and 28% had at least one AE with grade 3 or higher. The most altered was CRP that peaked in the 5(th) day after pleurodesis. Changes in CRP curve were less severe with the use of iodine when compared with the other two agents. CONCLUSIONS: Pleurodesis leads to important systemic inflammatory response detected by different serum markers. The occurrence of adverse events in this set of patients was great number of events with being marked as grade 3 or higher. |
format | Online Article Text |
id | pubmed-7399432 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-73994322020-08-13 Adverse events after pleurodesis in patients with malignant pleural effusion Terra, Ricardo Mingarini da Costa, Priscila Berenice Dela Vega, Alberto Jorge Monteiro Pêgo-Fernandes, Paulo Manuel J Thorac Dis Original Article BACKGROUND: Malignant pleural effusion (MPE) is an important sign of advanced disease in metastatic cancer. Pleurodesis is one option to treat recurrent MPE. The Inflammatory response after pleurodesis may lead to important adverse events (AE) in a set of very ill patients. METHODS: Retrospective analysis of patients submitted to pleurodesis (2009–2013). Clinical and laboratory data were collected. We compare the values in the day of pleurodesis, 2(nd), 5(th) and 10(th) days after. RESULTS: One hundred fourteen patients were undergone to pleurodesis with silver nitrate (46%), iodine (52%) and talc (2%). Female was the most frequent (86%) and the breast cancer was the most common primary site. The most frequent adverse event was low hemoglobin account (37), followed by pain (31). 68% of patients presented AEs and 28% had at least one AE with grade 3 or higher. The most altered was CRP that peaked in the 5(th) day after pleurodesis. Changes in CRP curve were less severe with the use of iodine when compared with the other two agents. CONCLUSIONS: Pleurodesis leads to important systemic inflammatory response detected by different serum markers. The occurrence of adverse events in this set of patients was great number of events with being marked as grade 3 or higher. AME Publishing Company 2020-07 /pmc/articles/PMC7399432/ /pubmed/32802429 http://dx.doi.org/10.21037/jtd-19-3850 Text en 2020 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Terra, Ricardo Mingarini da Costa, Priscila Berenice Dela Vega, Alberto Jorge Monteiro Pêgo-Fernandes, Paulo Manuel Adverse events after pleurodesis in patients with malignant pleural effusion |
title | Adverse events after pleurodesis in patients with malignant pleural effusion |
title_full | Adverse events after pleurodesis in patients with malignant pleural effusion |
title_fullStr | Adverse events after pleurodesis in patients with malignant pleural effusion |
title_full_unstemmed | Adverse events after pleurodesis in patients with malignant pleural effusion |
title_short | Adverse events after pleurodesis in patients with malignant pleural effusion |
title_sort | adverse events after pleurodesis in patients with malignant pleural effusion |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399432/ https://www.ncbi.nlm.nih.gov/pubmed/32802429 http://dx.doi.org/10.21037/jtd-19-3850 |
work_keys_str_mv | AT terraricardomingarini adverseeventsafterpleurodesisinpatientswithmalignantpleuraleffusion AT dacostapriscilaberenice adverseeventsafterpleurodesisinpatientswithmalignantpleuraleffusion AT delavegaalbertojorgemonteiro adverseeventsafterpleurodesisinpatientswithmalignantpleuraleffusion AT pegofernandespaulomanuel adverseeventsafterpleurodesisinpatientswithmalignantpleuraleffusion |